Loading...

ZFA-Logo

Literatur zu Weckmann, Chenot

PDF

1. Schmiegel W, Pox CP. S3-Leitlinie Kolorektales Karzinom (Konsultationsfassung) Version 1.0, 01.2013. Leitlinienprogramm Onkologie. AMWF-Register-Nummer (021/007OL)

2. Husmann G, Kaatsch P, Katalinic A, et al. Robert Koch Institut – Krebs in Deutschland 2007/2008 Häufigkeiten und Trends. RKI und GEKD 2012

3. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology 2010; 138: 2044–58

4. Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995; 64: 430–3

5. Gibbons DC, Sinha A, Phillips RK, Clark SK. Colorectal cancer: no longer the issue in familial adenomatous polyposis? Fam Cancer. 2011; 10 : 11–20

6. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006; 98: 920–31

7. Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev 2007; 16: 2533–47

8. Dai Z, Xu YC, Niu L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol. 2007; 13: 4199–206

9. Wang Y, Jacobs EJ, Patel AV, et al. A prospective study of waist circumference and body mass index in relation to colorectal cancer incidence. Cancer Causes Control 2008; 19: 783–792

10. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 2007; 86: 556–65

11. Tsoi KKF, Pau CYY, Wu WKK, Chan FKL, Griffiths S, Sung J. Cigarette smoking and the risk of colorectal cancer: A meta-analysis of prospective cohort studies. Clin Gastroenterol Hep 2009; 6: 682–88

12. Leufkens AM, Van Duijnhoven FJ, Siersema PD, et al. Cigarette smoking and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition study. Clin Gastroenterol Hepatol. 2011; 9: 137–44

13. Knekt P, Hakama M, Järvinen R, Pukkala E, Heliövaara M. Smoking and risk of colorectal cancer. Br J Cancer. 1998; 78: 136–9

14. Liang PS, Chen T-Y and Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer 2008; 124: 2406–15

15. Hoffmeister M, Schmitz S, Kamrodt E, et al. Male sex and smoking have a larger impact on the prevalence of colorectal neoplasia than family history of colorectal cancer. Clin Gastroenterol Hepatol 2010; 8: 870–6

16. Boyle T, Keegel T, Bull F, Heyworth J, Fritschi L. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J Natl Cancer Inst. 2012; 104: 1548–61

17. Doubeni CA, Major JM, Laiyemo AO, et al. Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst. 2012; 104: 1353–62

18. Isa ZM, Shah SA. Dietary patterns and risk of colorectal cancer: a systematic review of cohort studies (2000–2011). Asian Pac J Cancer Prev. 2012; 13: 4713–7

19. Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer. 2009; 125: 171–80

20. Wu S, Feng B, Li K, et al. Fish consumption and colorectal cancer risk in humans: a systematic review and meta-analysis. Am J Med 2012; 125: 551–9

21. Magalhães B, Peleteiro B, Lunet N. Dietary patterns and colorectal cancer: systematic review and meta-analysis. Eur J Cancer Prev. 2012; 21: 15–23

22. Kirkegaard H, Johnsen NF, Christensen J, Frederiksen K, Overvad K, Tjønneland A. Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study. BMJ 2010; 341: c5504

23. Astin M, Griffin T, Neal RD, Rose P, Hamilton W. The diagnostic value of symptoms for colorectal cancer in primary care: a systematic review. Br J Gen Pract. 2011; 61: e231–43

24. Adelstain B-A, Macaskill P, Chan SF, Katelaris PH, Irwig L. Most bowel cancer symptoms do not indicate colorectal cancer and polyps: a systematic review. BMC Gastroenterology 2011, 11: 65

25. Domagalski L, Gesenhues S. Onkologie. In: Gesenhues S, Ziesché R (Hrsg.). Praxisleitfaden Allgemeinmedizin, 5. Aufl. München: Elsevier, 2006: 1489–98

26. Fischer T, Huhn W, Freitag MH. Obstipation. In Kochen M (Ed.). Duale Reihe: Allgemeinmedizin und Familienmedizin, 4. Aufl. Stuttgart: Thieme, 2012: 350–56

27. Bundesministerium für Gesundheit. Bekanntmachung des Bundesausschusses der Ärzte und Krankenkassen über eine Änderung der Richtlinien über die Früherkennung von Krebserkrankungen (Krebsfrüherkennungs-Richtlinien) vom 21. Juni 2002.

28. Riens B, Schäfer M, Altenhofen L. Teilnahmeraten zur Beratung über Darmkrebs und zur Früherkennung im regionalen Vergleich. Zentralinstitut für die kassenärztliche Versorgung in Deutschland, 2011

29. Duffy MJ, Van Rossum LGM, Van Turenhout ST, et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J of Cancer 2011 Jan 1; 128: 3–11

30. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am J Gastroenterol 2008; 103: 1541–9

31. Brenner H, Arndt V, Stürmer T, Stegmaier C, Ziegler H, Dhom G. Long-lasting reduction of risk of colorectal cancer following screening endoscopy. Br J Cancer 2001; 85: 972–6

32. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013; 369: 1106–14

33. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149: 638–58

34. Oort FA, Terhaar Sive Droste JS, Van der Hulst RW, et al. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test. Aliment. Pharmacol Ther 2010; 31: 432–39

35. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. NEJM 2001; 345: 555–60

36. Rosman AS, Korsten MA. Effect of verification bias on the sensitivity of fecal occult blood testing: a meta-analysis. J Gen Intern Med 2010; 25: 1211–21

37. Pignone M, Campbell MK, Carr C, Phillips C. Meta-analysis of dietary restriction during fecal occult blood testing. EffClin Pract2001, 4: 150–6

38. Konrad G. Dietary interventions for fecal occult blood test screening: systematic review of the literature. Can Fam Physician 2010; 56: 229–38

39. Konrad G, Katz A. Practical advice based on a systematic review of the literature. Are medication restrictions before FOBT necessary? Can Fam Phys 2012; 9: 939–48

40. Cole SR, Young GP. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust 2001; 175: 195–8

41. Jellema P, Van der Windt DAWM, Bruinvels DJ, et al. Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis. BMJ 2010; 340: c1269

42. Mandelli G, Radaelli F, Paggi S, et al. Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: results from a nested in a cohort case-control study. Eur J Gastroenterol Hepatol. 2011; 23: 323–6

43. Carlson CM, Kirby KA, Casadei MA, Partin MR, Kistler CE, Walter LC. Lack of follow-up after fecal occult blood testing in older adults: inappropriate screening or failure to follow-up? Arch Intern Med 2011; 171: 249–56

44. Van Rossum LG, Vn Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82–90

45. Webendörfer S, Messerer P, Eberle F, Zober A. Eine Initiative sekundärer Prävention in der BASF Aktiengesellschaft. Dtsch Med Wochenschr. 2004; 129: 239–43

46. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99: 162–70

47. Terhaar sive Droste JX, Van Turenhout ST, Oort FA, et al. Faecal immunochemical test accuracy in patients referred for surveillane colonoscopy: a multi-centre cohort study. BMC Gastroenterol 2012, 12: 94

48. Trojan J, Povse N, Schröder O, Stein J. A new immunological test strip device for the rapid, qualitative detection of faecal occult blood. Z Gastroenterol. 2002; 40 :921–4

49. Health Quality Ontario. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis. Ont Health Technol Assess Ser. 2009; 9: 1–40

50. Tao S, Brenner H. Well adjusted qualitative immunochemical faecal occult blood tests could be a promising alternative for inexpensive, high-quality colorectal cancer screening. Eur J Cancer Prev 2013; 22: 305–10

51. www.rijksoverheid.nl/onderwerpen/bevolkingsonderzoek/documenten-en-publicaties/kamerstukken/2011/06/01/kamerbrief-invoering-bevolkingsonderzoek-darmkanker.html (letzter Zugriff am 21.03.2013)

52. www.zorg-en-gezondheid.be/uploadedFiles/NLsite_v2/Beleid/Adviesvraag %20Vlaams%20bevolkingsonderzoek%20naar%20dikkedarmkanker.pdf (letzter Zugriff am 08.03.2013)

53. Haug U, Hundt S, Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. B J Cancer 2008; 99, 133–5

54. Ahmed D, Danielsen SA, Aagesen TH, et al. A tissue-based comparative effectiveness analysis of biomarkers for early detection of colorectal tumors. Clin Transl Gastroenterol. 2012; 3: e27

55. Lind GE, Danielsen SA, Ahlquist T, et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer 2011; 10: 85

56. Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012; 142: 248–56

57. Warren JD, Xiong W, Bunker AM, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med 2011; 9: 133

58. Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology 2007; 132: 96–102

59. Van Rijn JC, Reitsma JB, Stoker J Bossuyt PM, Van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006; 101: 343–50

60. Heresbach D, Barrioz T, Lapalus MG, et al. Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies. Endoscopy 2008; 40: 284–90

61. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997; 112: 24–8

62. Beloosesky Y, Brinblat J, Weiss A, et al. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in the elderly patients. Arch Intern Med 2003; 163: 803–08

63. Lichtenstein GR, Cohen LB, Uribarri J. Review article: bowel preparation for colonoscopy – the importance of adequate hydration. Aliment Pharmacol Ther 2007; 26: 633–41

64. Riphaus A, Wehrmann T, Weber B, et al. S3-Leitlinie „Sedierung in der gastrointestinalen Endoskopie“ 2008. S3-Guidelines (AMWF-Register-Nr. 021/014)

65. Friedrich K, Stremmel W, Sieg A. Endoscopist-administered propofol sedation is safe – prospective evaluation of 10,000 patients in an outpatient practice. J Gastrointestin Liver Dis 2012; 3: 259–63

66. De Jonge V, Sint Nicolaas J, Van Baalen O, et al. The incidence of 30-day adverse events after colonoscopy among outpatients in the Netherlands. Am J Gastroenterol 2012; 107: 878–84

67. Ross WA. Colorectal cancer screening in evolution: Japan and the USA. J Gastroenterol Hepatol 2010; 25 (Suppl 1): S49–56

68. Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient colonosy and their risk factors in usual clinical practice. Gastroenterology 2008; 135: 1899–906

69. Ko CW, Riffle S, Michaels L, et al. Serious complications within 30 days of screening and surveillance colonoscopy are uncommon . Clin Gastroenterol Hepatol 2010; 8: 166–73

70. Suissa A, Bentur OS, Lachter J, et al. Outcome and complications of colonoscopy: a prospective multicenter study in Northern Israel. Diagn Ther Endosc 2012; 2012: 612542

71. Day LW, Kwon A, Inadomi JM, Walter LC, Somsouk M. Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc 2011; 4: 885–97

72. Levin TR, Zhao W, Conell C, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med 2006; 145: 880–6

73. Ferlitsch M, Reinhart K, Pramhas S, et al. Sex-specific prevalence of adenomas, advanced adenomas and colorectal cancer in individuals undergoing screening colonoscopy. JAMA 2011; 306: 1352–58

74. Pan A, Schlup M, Lübcke R, Chou A, Schultz M. The role of aspirin in post-polypectomy bleeding – a retrospective survey. BMC Gastroenterol 2012; 12: 138

75. Manocha D, Singh M, Mehta N, Murthy UK. Bleeding risk after invasive procedures in aspirin/NSAID users: polypectomy study in veterans. Am J Med. 2012; 125: 1222–7

76. Feagins LA, Uddin FS, Davila RE, Harford WV, Spechler SJ. The rate of post-polypectomy bleeding for patients on uninterrupted clopidogrel therapy during elective colonoscopy is acceptably low. Dig Dis Sci 2011; 56: 2631–8

77. Wood JJ, Foy CJ, Valori R, et al. Does use of a colonoscopy imaging device improve performance? A cohort study. Surg Endosc 2012; 26: 3616–21

78. Zorzi M, Baracco S, Fedato C, et al. Screening for colorectal cancer in Italy, 2009 survey. Epidemiol Prev 2011; 35 (5–6 Suppl 5): 55–77

79. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009; 150: 1–8

80. Leung K, Pinsky P, Laiyemo AO, et al. Ongoing colorectal cancer risk despite surveillance colonoscopy: the Polyp Prevention Trial Continued Follow-up Study. Gastrointest Endosc 2010; 71: 111–7

81. Rex DK, Cummings OW, Helper DJ, et al. 5-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons [see comment]. Gastroenterology 1996; 111: 1178–81

82. Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med 2013; 158: 312–20

83. Elmunzer BJ, Hayward RA, Schoenfeld PS, Saini SD, Deshpande A, Waljee AK. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 2012; 9: e1001352

84. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial – SCORE. J Natl Cancer Inst 2011; 103: 1310–22

85. Atkin W, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicenter randomized controlled trial. Lancet 2010; 375: 1624–33

86. Littlejohn C, Hilton S, Macfarlane GJ, Phull P. Systematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancer. Br J Surg. 2012; 99: 1488–500

87. Mang T, Schima W. CT-Kolonographie. Stuttgart: Thieme 2009

88. Wijkerslooth de Weerdesteyn TR. Population screening for colorectal cancer by colonoscopy (Dissertation). Amsterdam: UvA-DARE, 2013

89. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centers. Gut 1988; 29: 206–17

90. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526–35

91. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998–2010. Gastroenterology 2012; 143: 382–9

92. Selinger CP, Andrews JM, Titman A, et al. Long-term follow up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013. pii: S1542–3565(13)00708–8

93. Jess T, Simonsen J, Jørgensen KT, Vestergaard Pedersen B, Munk N, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143: 375–81

94. Söderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009; 136: 1561–7

95. Jess T, Loftus EV, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. Gastroenterology 2006; 10: 1039–46

96. Shaukat A, Virnig DJ, Salfiti NI, Howard DH, Sitaraman SV, Liff JM. Is inflammatory bowel disease an important risk factor among older persons with colorectal cancer in the United States? A population-based case-control study. Dig Dis Sci 2011; 56: 2378–83

97. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment. Pharmacol Ther 2006; 23: 1097–104

98. Brackmann S, Andersen SN, Aamodt G, et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol 2009, 44: 46–55

99. Mooiweer E, Baars JE, Lutgens MWMD, et al. Disease severity does not affect the interval between IBD diagnosis and the development of CRC: Results from two large, Dutch case series. J Crohns Colitis 2012; 4: 435–40

100. Nguyen GC. A tale of two cohorts: are we overestimating the risk of colorectal cancer in inflammatory bowel disease? Gastroenterology 2012; 143: 288–90

101. Lukas M. Inflammatory Bowel Disease as a risk factor for colorectal cancer. Dig Dis 2010; 28: 619–24

102. Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am 2006; 35: 675–712

103. Cooper K, Squires H, Carrol C, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technology Assess 2010; 14: 1–206

104. Butterworth JR. Chemoprevention of colorectal cancer in inflammatory bowel disease. Digest Liv Dis 2009; 41: 338–9

105. Söderlund S, Granath F, Broström O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology 2010; 138: 1697–703

106. Askling J, Dickman PW, Karlén P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001; 120: 1356–62

107. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001; 96: 2992–3003

108. Butterworth AS, Higgins JPT, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: A meta-analysis. Eur J Cancer 2006; 42: 216–27

109. Hall NR, Bishop DT, Stephenson BM, Finan PJ. Hereditary susceptibility to colorectal cancer. Relatives of early onset cases are particularly at risk. Dis Colon Rectum 1996; 39: 739–43

110. Ait Ouakrim D, Lockett T, Boussioutas A, et al. Screening participation predictors for people at familial risk of colorectal cancer: a systematic review. Am J Prev Med. 2013; 44: 496–506

111. Burn J, Mathers J, Bishop DT. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). Recent Results Cancer Res 2013; 191: 157–83

112. Holinski-Feder E, Morak M. Familäre adenomatöse Polyposis und andere Polyposissyndrome. Gastroenterologe 2010; 5: 7–15

113. Win AK, Lindor NM, Winship I, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch symdrome. J Natl Cancer Inst 2013; 105: 274–9

114. Lamberti C, Mangold E, Pagenstecher C, et al. Frequency of hereditary non-polposis colorectal cancer among unselected patients with colorectal cancer in Germany. Digestion 2006; 74: 58–67

115. Van Lier MG, Leenen CH, Wagner A, et al. Yield of routine molecular analyses in colorectal cancer patients ?70 years to detect underlying Lynch syndrome. J Pathol. 2012; 226: 764–74

116. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008; 26: 5783–8

117. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261–8

118. Griffith JM, Lewis CL, Brenner AR, Pignone MP. The effect of offering different numbers of colorectal cancer screening test options in a decision aid: a pilot randomized trial. BMC Med Inform Decis Mak 2008 Jan 24; 8: 4

119. Jimbo M, Rana G, Hawley S, et al. What is lacking in current decision aids on cancer screening? Ca Cancer J Clin 2013; 63: 193–214

120. Waldmann A, Raspe H, Katalinic A. Darmkrebsrisiko bei familiären und hereditären Risikopersonen unter 55 Jahren. Z Gastroenerol 2009; 47: 1052–8

121. Barret B, McKenna P. Communicating benefits and risks of screening for prostate, colon, and breast cancer. Fam Med 2011; 43: 248–53

122. Galesic M, Gigerenzer , Strauinger N. Natural frequencies help older adults and people with low numeracy to evaluate medical screening tests. Med Decis Mak 2009; 29: 368–71

123. Lewis CL, Golin CE, DeLeon C, et al. A targeted decision aid for the elderly to decide whether to undergo colorectal cancer screening: development and results of an uncontrolled trial. BMC Med Inform Decis Mak 2010, 10: 54

124. Steckelberg A, Mühlhauser I. Darmkrebs Screening Früherkennung. Universität Hamburg, 2008

125. Steckelberg A, Hülfenhaus C, Haastert B, Mühlhauser I. Effect of evidence based risk information on „informed choice“ in colorectal cancer screening: randomised controlled trial. BMJ 2011; 342: d3193


(Stand: 02.12.2013)

Als Abonnent können Sie die vollständigen Artikel gezielt über das Inhaltsverzeichnis der jeweiligen Ausgabe aufrufen. Jeder Artikel lässt sich dann komplett auf der Webseite anzeigen oder als PDF herunterladen.